Some source information from Gemini Pro:
Monitoring surrogates of gut “decay” and bacterial translocation through commercial laboratories typically involves measuring LPS-binding protein (LBP), Zonulin, and Intestinal Fatty Acid-Binding Protein (FABP2/I-FABP). While direct serum LBP testing is primarily offered through specialized clinical or research panels, standard commercial labs provide these via specialty branches or partner laboratories.
1. Quest Diagnostics (via Cleveland HeartLab)
Quest Diagnostics provides advanced gut integrity testing primarily through its specialty division, Cleveland HeartLab (CHL). These tests are specifically designed to monitor intestinal barrier breakdown and the resulting systemic inflammation.
-
Intestinal Barrier Assessment (CHL): This panel is the most direct way to monitor the “decay” markers mentioned. It typically includes:
-
Zonulin (Serum): A protein that modulates intestinal permeability by disassembling tight junctions (Giron et al., 2022). High levels are a validated marker for “leaky gut” and increased bacterial translocation.
-
FABP2 / I-FABP (Intestinal Fatty Acid-Binding Protein): A protein specifically located in the mucosal layer of the small intestine. It is released into the circulation upon enterocyte injury, serving as a sensitive marker for the physical “decay” of the gut lining (Hernandez et al., 2025; Zaragoza-García et al., 2023).
-
Test Ordering: These are often ordered through Quest as CHL-specific codes. While standard Quest codes vary by region, the Zonulin (Serum) test is frequently identified by Quest code 94605.
2. Labcorp
Labcorp offers individual markers for monitoring intestinal permeability and the translocation of bacterial components.
-
Zonulin, Family (Serum): Labcorp provides a quantitative serum assay for Zonulin.
-
Test Number: 822765
-
Clinical Utility: Used as a physiological driver of tight junction permeability; elevated levels enable the translocation of bacterial and fungal products into the bloodstream (Giron et al., 2022).
-
Complementary Inflammatory Markers: Labcorp often pairs gut barrier testing with systemic markers of bacterial translocation response, such as High-Sensitivity C-Reactive Protein (hs-CRP) (Labcorp code: 006627), which reflects the systemic inflammation triggered by circulating lipopolysaccharides (Hall et al., 2023).
3. Specialized “Gut Barrier” Panels (Reference Labs)
For direct measurement of LPS-binding protein (LBP) itself—which opsonizes gram-negative bacteria and reflects chronic LPS translocation—practitioners often use reference labs that Quest and Labcorp can act as collection sites for:
-
KBMO Diagnostics Gut Barrier Panel: This is the most comprehensive “surrogate of decay” test. It measures immune responses (IgG/IgA) to four specific markers: LBP, Zonulin, Occludin, and LPS (Endotoxin).
-
Mayo Clinic Laboratories: Often serves as a reference lab for Quest/Labcorp for specific translocation markers. Their LBP test (Code: LBP) measures serum levels as an acute-phase protein that peaks shortly after bacteremia and reflects the liver’s response to gut-derived toxins (Barchetta et al., 2023; Opal et al., 1999).
References
Barchetta, I., Cimini, F. A., Sentinelli, F., Chiappetta, C., Di Cristofano, C., Silecchia, G., Leonetti, F., Baroni, M. G., & Cavallo, M. G. (2023). Reduced Lipopolysaccharide-Binding Protein (LBP) Levels Are Associated with Non-Alcoholic Fatty Liver Disease (NAFLD) and Adipose Inflammation in Human Obesity. International Journal of Molecular Sciences, 24(24), 17174. https://doi.org/10.3390/ijms242417174 Cited by: 34
Giron, L. B., Peluso, M. J., Ding, J., Kenny, G., Zilberstein, N. F., Koshy, J., Hong, K. Y., Rasmussen, H., Miller, G. E., Bishehsari, F., Balk, R. A., Moy, J. N., Hoh, R., Lu, S., Goldman, A. R., Tang, H.-Y., Yee, B. C., Chenna, A., Winslow, J. W., … Keshavarzian, A. (2022). Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-κB signaling. JCI Insight, 7(14). https://doi.org/10.1172/jci.insight.164813 Cited by: 86
Hall, D. A., Voigt, R. M., Cantu-Jungles, T. M., Hamaker, B., Engen, P. A., Shaikh, M., Raeisi, S., Green, S. J., Naqib, A., Forsyth, C. B., Chen, T., Manfready, R., Ouyang, B., Rasmussen, H. E., Sedghi, S., Goetz, C. G., & Keshavarzian, A. (2023). An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants. Nature Communications, 14(1). An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants | Nature Communications Cited by: 121
Hernandez, J., Rodriguez, J. B., Trak-Fellermeier, M. A., Galvan, R., Macchi, A., Martinez-Motta, P., & Palacios, C. (2025). Suboptimal vitamin D status and overweight/obesity are associated with gut integrity and inflammation in minority children and adolescents: A cross-sectional analysis from the MetA-bone trial. Nutrition Research, 133, 13–21. Redirecting Cited by: 4
Opal, S. M., Scannon, P. J., Vincent, J.-L., White, M., Carroll, S. F., Palardy, J. E., Parejo, N. A., Pribble, J. P., & Lemke, J. H. (1999). Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS-Binding Protein in Patients with Severe Sepsis and Septic Shock. The Journal of Infectious Diseases, 180(5), 1584–1589. https://doi.org/10.1086/315093Cited by: 798
Zaragoza-García, O., Castro-Alarcón, N., Pérez-Rubio, G., Falfán-Valencia, R., Briceño, O., Navarro-Zarza, J. E., Parra-Rojas, I., Tello, M., & Guzmán-Guzmán, I. P. (2023). Serum Levels of IFABP2 and Differences in Lactobacillus and Porphyromonas gingivalis Abundance on Gut Microbiota Are Associated with Poor Therapeutic Response in Rheumatoid Arthritis: A Pilot Study. International Journal of Molecular Sciences, 24(3), 1958. https://doi.org/10.3390/ijms24031958